CYduct Diagnostics, Inc.
CYDX
Other OTC0.42
USD
- -
- -
CYduct Diagnostics, Inc.
CYDX
(Other OTC)
Recent
price
0.42
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CYduct Diagnostics, Inc. (CYDX) develops, produces and markets medical devices and diagnostic technologies focused on intraductal assessment, early detection and risk evaluation of breast cancer within the mammary ducts; its core products include the HALO noninvasive system for collecting nipple aspirate fluid (NAF) samples to enable proteomic and molecular analysis of breast cancer biomarkers, the MammoView fiberoptic imaging platform for real-time intraductal visualization, cell collection and future biopsy capabilities, and advanced precision medicine-based risk assessment tests utilizing multi-biomarker combinations for personalized breast health monitoring. Headquartered in Westport, Connecticut, and founded in 1986, the company formerly known as Solos Endoscopy, Inc. until its name change in December 2020, operates in the women's health sector targeting clinicians, high-risk patients and women with dense breast tissue across the United States. CYduct Diagnostics emphasizes intraductal approaches to improve early intervention outcomes, with geographic focus on the U.S. market and no disclosed subsidiaries or parent entities. Recent developments include the granting of a patent for its precision medicine-based breast cancer risk assessment test; positive study results validating biomarker combinations for enhanced breast cancer assessment; receipt of a grant from the Sharon D. Lund Foundation via the Dr. Susan Love Foundation’s 11th International Symposium on the Human Breast to advance proteomic testing; and participation in the 10th Annual Yale Innovation Summit, alongside support for initiatives like the Find It Early Act and Camp Breastie 2023. In 2021, the company completed a strategic acquisition of assets from HHC Preferred LLC, including patented NAF collection technology, inventory, regulatory approvals and manufacturing tools to bolster its intraductal diagnostic platform. These advancements underscore CYduct Diagnostics' shift toward integrated precision diagnostics and clinical research leadership in breast health.
Cyduct Diagnostics To Participate at the 10th Annual Yale Innovation Summit
CYduct Diagnostics Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer
CYduct Diagnostics Proudly Supports the "Find It Early Act" to Advance Women's Health
CYduct Diagnostics Inc. Advocates for Breast Cancer Awareness Month: Pioneering Innovation and Early Detection
Cyduct Diagnostics Recognizes a Visionary Leader in Breast Health: Dr. Susan Love